Larimar Advances Nomlabofusp Toward 2026 BLA Submission

Larimar Therapeutics ( (LRMR) ) has issued an update.

On March 9, 2026, Larimar Therapeutics posted an updated corporate presentation outlining progress in its nomlabofusp program for Friedreich’s ataxia and ongoing regulatory engagement. The company reported that the FDA has granted nomlabofusp Breakthrough Therapy Designation, along with multiple U.S. and global expedited development designations, based on open-label data showing restoration of FXN levels to those seen in asymptomatic carriers and consistent directional improvements in key functional measures.

Larimar detailed continued alignment with the FDA to target a June 2026 BLA submission for nomlabofusp, with skin FXN levels under consideration as a novel surrogate endpoint and Upright Stability Score confirmed as a clinically relevant primary endpoint for a global Phase 3 study. The company highlighted a series of planned near-term milestones, including topline open-label data and initiation of Phase 3 screening in the second quarter of 2026, and reported pro forma cash and investments of about $244.5 million as of December 31, 2025, supporting a projected cash runway into the second quarter of 2027.

The most recent analyst rating on (LRMR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.

Spark’s Take on LRMR Stock

According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.

Score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn) and bearish technical signals (below key moving averages with negative MACD). Positive clinical/regulatory progress for the lead program provides support, but valuation remains constrained by ongoing losses and no dividend.

To see Spark’s full report on LRMR stock, click here.

More about Larimar Therapeutics

Larimar Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare, debilitating diseases, with a primary emphasis on Friedreich’s ataxia (FA). Its lead product candidate, nomlabofusp (CTI-1601), is a protein replacement therapy designed to address the root cause of FA by restoring frataxin (FXN) levels in mitochondria to potentially modify disease progression.

FA affects roughly 20,000 patients globally, including about 5,000 in the U.S., and currently has only one approved therapy that does not address frataxin deficiency. Larimar is targeting this high unmet medical need population, including a large proportion of patients who present before age 14 and face progressive neurological decline, cardiometabolic complications, and reduced life expectancy.

Average Trading Volume: 4,028,584

Technical Sentiment Signal: Buy

Current Market Cap: $446.8M

See more insights into LRMR stock on TipRanks’ Stock Analysis page.